Privately held biologics medical device firm NovaBone Products has secured CE mark approval for its NovaTape and NovaPlug dental wound dressing products.
NovaTape and NovaPlug are collagen-based products, which will enable to manage soft tissue oral wounds and sores.
The new products will allow to manage dental sores, oral ulcers (non-infected or viral), periodontal surgical wounds, suture sites, burns, extraction sites, surgical and traumatic wounds.
Since last year, the company has been developing collagen-based products for the medical community.
NovaBone Products president Art Wotiz said: “The CE mark approval is a major milestone for our company and a benefit to physicians and dentists in the European Union.
“NovaTape and NovaPlug are exceptionally user-friendly and proven to be effective for a range of indications.
“It is important to note that NovaBone now has comprehensive capabilities to produce intuitively-designed bioactive collagen composites and collagen-only products that meet the demands of medical professionals.”
In March 2015, the company secured 501(k) clearance from the US Food and Drug Administration (FDA) for its NovaTape and NovaPlug collagen wound dressings.
The company also produces of bioactive glass bone graft devices for the orthopedic community. It produces seven devices within the field of orthopedics and six for dental indications.